The Food and Drug Administration has loosened its label on testosterone replacement therapy, or TRT, for short, in an attempt by President Donald Trump’s administration to reverse the historic testosterone decline among young men.

TRT was recently considered to be harmful to men over potential risks of developing prostate cancer and/or heart complications. However, an FDA panel in December 2025 determined, through science-based evidence, that this is not the case, and the supplement helps more than it harms young men.

The FDA hopes the new label on TRT will encourage men who are testosterone deficient to seek the treatment and reverse the country’s epidemic of obesity, substance abuse, suicide, and mental health challenges caused, in part, by a lack of testosterone.

“20–25% of young men have testosterone deficiency,” HHS Assistant Secretary for Health Admiral Brian Christine, MD, told The Daily Signal. “This could be a product of environmental factors. It affects our libido, our vitality, our desire for intimacy. [Testosterone] is an important way to improve the health span and the quality of life for men.”

“Low energy, low libido, low vitality, difficulty maintaining a lean muscle mass, and we know that replacing their testosterone, and getting their levels back up is extremely healthy,” Christine added.

Christine says that lowering the barrier of entry for men who need the substance could be instrumental in reversing the epidemic of idiopathic hypogonadism, low testosterone levels without identifiable cause, or testosterone levels that simply drop over time without an identifiable driving cause.

More here

Tagged: Partner BACK TO HOMEPAGE